ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk ...Middle East

Medscape - News
New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease. Medscape Medical News

Hence then, the article about esc backs sglt2i plus glp 1 in diabetes with high cvd risk was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk )

Apple Storegoogle play

Last updated :

Also on site :



Latest News